SNDX News and Press, Syndax Pharmaceuticals Inc. From 04/26/21

Insider buying decreased significantly last week. Notable Insider Buys: The Greenbrier Companies, Inc., GEE Group, Inc., Landec Corporation, Syndax Pharmaceuticals, Inc., and Bank of Marin Bancorp. Notable Insider Sells: Coinbase Global, Inc., Facebook, Inc., The Charles Schwab Co...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks bounced back on Friday following a pair of strong U.S. economic reports and as investors reassessed concerns from news the previous day that the Bid...

Shares of Syndax Pharmaceuticals (NASDAQ: SNDX) were sinking 28% as of 11:32 a.m. EDT on Tuesday. This big decline came after the company reported positive results from a phase 1 study evaluating SNDX-5613 in treating leukemia. Normally, when a biotech stock plunges after an...

Gainers: Sequential Brands (SQBG) +23%.Kansas City Southern (KSU) +16%.180 Life Sciences (ATNF) +14%.Moxian (MOXC) +12%.Purple Biotech (PPBT) +11%.AST SpaceMobile (ASTS) +11%.Sharps Compliance (SMED) +10%.Takung Art (TKAT) +10%.Summer Infant (SUMR) +9%.Puyi (PUYI) +9%.Losers:&#...

Gainers: Purple Biotech (PPBT) +9%, NeuroBo Pharmaceuticals (NRBO) +7%, Obalon Therapeutics (OBLN) +7%, Dare Bioscience (DARE) +4%, Hoth Therapeutics (HOTH) +2%.Losers: Syndax Pharmaceuticals (SNDX) -28%, Zai Lab (ZLAB) -13%, KalVist...

Syndax Pharmaceuticals (SNDX) announces updated positive data from Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with mixed lineage leukemia rearranged (MLLr) and nucleophosmin (NPM1c) mutant relapsed/refractory (R/R) acute leukemias.As of...

Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias - 48% overall response rate in patients with MLLr or NPM1c; 67% of responders achieved mini...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias - Event to be webcast live on Tuesday, April 20, 2021 at 8:00 a.m. ET - PR Newswire WALTHAM, M...

Syndax Pharmaceuticals (SNDX) is up ~4.4% in after-hours on the announcement of Orphan Drug Designation granted by the FDA for its anti-CSF-1R monoclonal antibody Axatilimab for the treatment of idiopathic pulmonary fibrosis (“IPF”).Given for drug candidates ...